Gastric Cancer Complicated With Bleeding

Peking University

Status: Not yet enrolling

Conditions: Gastric Cancer

Treatments: Drug: systematic therapy

Study type: Observational

Funder types: Other

Identifiers

NCT06522542

IRB00006761-M2023544

Details and patient eligibility

About

To investigate the impact of bleeding on the survival and treatment-related adverse events (TRAEs) of gastric cancer patients.

Full description

We will retrospectively enroll patients diagnosed with advanced or metastatic gastric cancer at the Department of Medical Oncology and Radiation Sickness of Peking University Third Hospital. The retrospective study aims to investigate the impact of bleeding on treatment-related adverse events (TRAEs) for gastric cancer patients receiving systematic anticancer treatment, assess the influence of bleeding on the survival of patients.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients older than 18 years;
2. A histologically confirmed diagnosis of advanced or metastatic gastric cancer;
3. The initial anticancer treatment was systematic therapy, including chemotherapy, targeted therapy or immune checkpoint inhibitor (ICI);
4. No history of gastrectomy before systematic therapy.

Exclusion criteria

1. Incompletable clinical data;
2. Siewert I type esophagus cancer.

Trial design

200 participants in 2 patient groups

Test group

Description:

Gastirc cancer with bleeding at first diagnosis

Treatment:

Drug: systematic therapy

Control group

Description:

Gastirc cancer without bleeding at first diagnosis

Treatment:

Drug: systematic therapy